リスパダール細粒１％
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00734 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 41 |
| 日本商品名（例） | リスパダール内用液１ｍｇ／ｍＬ ０．１％, リスパダール細粒１％, リスパダール細粒１％（選） |
承認適応症（KEGG）
統合失調症
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99% | DL |
| 2 | autism susceptibility 1 | 99% | DL |
| 3 | autism spectrum disorder | 99% | DL |
| 4 | gaze palsy, familial horizontal, with progressive scoliosis | 99% | DL |
| 5 | asperger syndrome, susceptibility to | 99% | DL |
| 6 | amelocerebrohypohidrotic syndrome | 99% | DL |
| 7 | Phelan-McDermid syndrome | 99% | DL |
| 8 | trichotillomania | 99% | DL |
| 9 | major affective disorder | 99% | DL |
| 10 | bipolar disorder | 98% | DL |
| 11 | Tourette syndrome | 98% | DL |
| 12 | intellectual disability | 98% | DL |
| 13 | autism, susceptibility to | 98% | DL |
| 14 | chromosome 15q11.2 deletion syndrome | 98% | DL |
| 15 | 16q24.3 microdeletion syndrome | 98% | DL |
| 16 | schizophrenia | 98% | DL |
| 17 | occipital pachygyria and polymicrogyria | 98% | DL |
| 18 | attention deficit-hyperactivity disorder | 98% | DL |
| 19 | distal 17p13.3 microdeletion syndrome | 98% | DL |
| 20 | epsilon-trimethyllysine hydroxylase deficiency | 98% | DL |
| 21 | Malan overgrowth syndrome | 98% | DL |
| 22 | faciodigitogenital syndrome | 97% | DL |
| 23 | hydranencephaly (disease) | 97% | DL |
| 24 | retinal dystrophy with or without extraocular anomalies | 97% | DL |
| 25 | myopia X-linked | 97% | DL |
| 26 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 97% | DL |
| 27 | myopia 26, X-linked, female-limited | 97% | DL |
| 28 | congenital disorder of glycosylation with defective fucosylation | 97% | DL |
| 29 | syndromic myopia | 97% | DL |
| 30 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 97% | DL |
| 31 | hypotonia, infantile, with psychomotor retardation and characteristic facies | 96% | DL |
| 32 | trigeminal nerve neoplasm | 96% | DL |
| 33 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 96% | DL |
| 34 | atypical glycine encephalopathy | 96% | DL |
| 35 | attention deficit hyperactivity disorder, inattentive type | 96% | DL |
| 36 | autism (disease) | 94% | DL |
| 37 | chondromyxoid fibroma | 94% | DL |
| 38 | specific developmental disorder | 94% | DL |
| 39 | restless legs syndrome | 93% | DL |
| 40 | pyruvate carboxylase deficiency disease | 91% | DL |
| 41 | myofascial pain syndrome | 90% | DL |
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。